Investigation of Cancer Cell Extravasation Through mRNA Analysis of Organ-specific Endothelial Cells and Microfluidics

Breast Cancer Metastatic Clinical Trial

Official title:

Identification of Novel Genes Involved in Cancer Cell Extravasation by Transcriptional Profiling of Primary Organ-specific Endothelial Cells and in Vitro 3D Models

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04047459
• Other study ID #: BRCP USA
• Status: Completed
• Start date: June 6, 2016
• Est. completion date: May 31, 2018

Study information

• Verified date: August 2019
• Source: Istituto Ortopedico Galeazzi
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The project aims at unraveling the role of organ-specific endothelia mediating the preferential metastasisation of breast cancer cells to bone by using a multi-faceted approach, integrating microfluidics and transcriptomic profiling. Based on a recently study published by the investigators [Jeon et al., PNAS 2015], it can be hypothesized that phenotypic differences at the level of organ-specific endothelial cells are able to drive the preferential extravasation of breast cancer cells to specific sites. Hence, the transcriptional profile of primary organ-specific endothelial cells derived from healthy patients (i.e. non-affected by breast cancer) will be analyzed to identify phenotypic differences between organ-specific populations of endothelial cells. These analyses will allow to identify potential target genes involved in the organ-specific extravasation of cancer cells (i.e. genes differentially expressed by endothelia of preferential and non-preferential metastasisation sites). The selected genes will be silenced and the effect of gene silencing will be evaluated through microfluidic in vitro organ-specific 3D models designed to study cancer cell extravasation.

Description:

In particular, the main aim of the study will be to highlight differences between bone and skeletal muscle microenvironments, which are respectively preferential and non-preferential metastasisation sites for breast cancer cells, in order to identify specific pathways driving breast cancer cells extravasation. To this purpose, differences in the transcriptional profile of ECs derived from bone and muscle endothelium will be investigated. These analyses will be used to select target genes differentially expressed by bone- and muscle-specific ECs. Then, ECs obtained from bone and muscle endothelium will be respectively used to mimic bone and muscle microvessel environments in microfluidic in vitro 3D models allowing for the study of breast cancer cell extravasation. The genes selected according to the results of the transcriptomic analysis (e.g. genes expressed in ECs derived from bone endothelium, but not expressed in ECs derived from muscle endothelium) will be silenced and the effect of gene silencing will be evaluated monitoring breast cancer cell extravasation in order to verify the involvement of the selected genes in this process.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: May 31, 2018
• Est. primary completion date: May 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• age between 18-65 years

• patients undergoing cruciate ligament surgery or hip arthroplasty

• subscription of informed consent

Exclusion Criteria:

• HIV, HCV, HBV, TPHA viral

Related Conditions & MeSH terms

• Breast Cancer Metastatic

Intervention

Other:
• Tissue samples collection and cells isolation
During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.

Locations

Country	Name	City	State
Italy	IRCCS Galeazzi Orthopedic Hospital	Milan

Sponsors (1)

Lead Sponsor	Collaborator
Istituto Ortopedico Galeazzi

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genes differentially expressed by bone and muscle ECs	Differential expression of genes will be determined by transcriptomic analysis of mRNA (with genome-wide mRNA array tools) derived from bone and muscle ECs	31/05/2018
Secondary	Differences in adhesive properties of bone and muscle ECs	Bone and muscle derived ECs will be compared in terms of immunofluorescent staining for adhesion molecules (ICAM-1, E-selectin)	31/05/2018
Secondary	Differences in cell adhesion between bone and muscle ECs	Bone and muscle derived ECs will be compared in terms of number of cells adhered (neutrophils, ...)	31/05/2018
Secondary	Differences in angiogenic potential between bone and muscle ECs	Bone and muscle derived ECs will be compared in terms of angiogenic sprouting, by analyzing immunofluorescence images	31/05/2018
Secondary	Selection of potential target genes involved in breast cancer metastasis	Differentially expressed genes potentially involved in breast cancer cells extravasation and metastasis formation	31/05/2018